Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction is currently active. The SELL prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc. is trending in the completely wrong direction and now has a performance of 33.44%. Dividends of €3.58 are taken into consideration when calculating the performance. This prediction currently runs until 17.04.26. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.921% | -3.921% |
| iShares Core DAX® | 3.023% | 2.202% |
| iShares Nasdaq 100 | 3.561% | 1.325% |
| iShares Nikkei 225® | 6.618% | 5.707% |
| iShares S&P 500 | 2.635% | 1.008% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
19:28
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24

